SCHEMBL26318064

SCHEMBL26318064

CCOPCc1ccc2c(OC)cc(C(=O)OCC)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.46
BCL2L1 Q07817 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAOB P27338 1/20 0.38
MAPT P10636 5/20 0.38
GAA P10253 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
HTT P42858 2/20 0.37
LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25410001 0.83 HSD17B2 (0.50) HSD17B2BCL2L1SMN1; SMN2NPC1RAB9A
SCHEMBL25409586 0.80 HSD17B2 (0.55) HSD17B2BCL2L1SMN1; SMN2NPC1RAB9A
SCHEMBL25412103 0.78 HSD17B2 (0.45) HSD17B2BCL2L1SMN1; SMN2NPC1RAB9A
SCHEMBL15774677 0.78 HSD17B2 (0.52) HSD17B2BCL2L1SMN1; SMN2NPC1RAB9A
SCHEMBL18031420 0.74 HSD17B2 (0.51) HSD17B2BCL2L1SMN1; SMN2NPC1RAB9A
SCHEMBL2390984 0.70 HSD17B2 (0.52) HSD17B2SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL13057635 0.70 BCL2L1 (0.47) HSD17B2BCL2L1SMN1; SMN2NPC1RAB9A
SCHEMBL16474353 0.69 BCL2L1 (0.52) HSD17B2BCL2L1SMN1; SMN2CA12CA1
SCHEMBL13057669 0.69 BCL2L1 (0.49) HSD17B2BCL2L1SMN1; SMN2NPC1RAB9A
SCHEMBL13057674 0.69 CA12 (0.51) HSD17B2BCL2L1MAOBGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023164680-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. (US) 2023-08-31 WO disclosed